uniQure (NASDAQ:QURE) Given “Buy” Rating at Chardan Capital

Chardan Capital restated their buy rating on shares of uniQure (NASDAQ:QURE) in a report issued on Thursday,Benzinga reports. The firm currently has a $53.00 price target on the biotechnology company’s stock.

Other equities analysts also recently issued research reports about the stock. William Blair reiterated a “market perform” rating on shares of uniQure in a research note on Tuesday, November 11th. Benchmark reaffirmed a “buy” rating on shares of uniQure in a research report on Tuesday, November 4th. UBS Group set a $95.00 price objective on uniQure in a report on Thursday, September 25th. Mizuho raised their target price on uniQure from $30.00 to $60.00 and gave the stock an “outperform” rating in a research report on Thursday, September 25th. Finally, Cantor Fitzgerald increased their price target on shares of uniQure from $47.00 to $80.00 and gave the company an “overweight” rating in a research note on Thursday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $64.42.

uniQure Stock Performance

Shares of uniQure stock opened at $22.74 on Thursday. The business has a 50-day simple moving average of $45.23 and a 200-day simple moving average of $26.05. The company has a market cap of $1.42 billion, a PE ratio of -5.18 and a beta of 0.59. uniQure has a one year low of $6.14 and a one year high of $71.50. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Monday, November 10th. The biotechnology company reported ($1.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.53). uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%.The firm had revenue of $3.70 million during the quarter, compared to analysts’ expectations of $4.46 million. On average, equities research analysts forecast that uniQure will post -3.75 EPS for the current fiscal year.

Insider Transactions at uniQure

In related news, Director Robert Gut sold 31,434 shares of the company’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $27.26, for a total value of $856,890.84. Following the completion of the sale, the director owned 40,145 shares in the company, valued at $1,094,352.70. This represents a 43.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Jack Kaye sold 38,810 shares of the stock in a transaction on Tuesday, November 4th. The stock was sold at an average price of $30.34, for a total transaction of $1,177,495.40. Following the sale, the director owned 20,439 shares of the company’s stock, valued at approximately $620,119.26. This represents a 65.50% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 314,560 shares of company stock worth $12,362,568 in the last three months. Corporate insiders own 4.79% of the company’s stock.

Institutional Investors Weigh In On uniQure

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Aberdeen Group plc increased its stake in shares of uniQure by 24.2% during the second quarter. Aberdeen Group plc now owns 2,750,714 shares of the biotechnology company’s stock worth $38,345,000 after acquiring an additional 535,163 shares during the period. Jennison Associates LLC purchased a new stake in uniQure in the 2nd quarter valued at approximately $1,952,000. Y Intercept Hong Kong Ltd purchased a new stake in uniQure in the 2nd quarter valued at approximately $872,000. JPMorgan Chase & Co. increased its position in uniQure by 471.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock worth $25,199,000 after purchasing an additional 1,491,486 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of uniQure during the 1st quarter worth approximately $2,562,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.